Finland· FI-REL-REL51669

Bydureon

A exenatide product containing exenatide, registered in Finland by AstraZeneca AB. The same ATC class is registered in 10 of our 19 countries.

ATC A10BJ01

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedBydureonATCA10BJ01REGISTER NO.FI-REL-REL51669PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Exenatide is registered in 10 of 19 countries.

Countries holding a registration under ATC A10BJ01 (exenatide), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 7 of them publish a price we can compare per daily dose

Exenatide · ATC A10BJ01

10 / 19 countries

  • Belgiumprice
  • Finlandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of exenatide costs, country by country.

Normalised to the WHO defined daily dose (15 mcg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Exenatide · price per daily dose (15 mcg)

USD · FX 28 Sept 2026

  • CH Switzerland$0.26
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Exenatide
Manufacturer
AstraZeneca AB
Country
Finland (FI)
ATC code
A10BJ01
ATC class
Exenatide
Defined daily dose
15 mcg, P
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

404 interactions on record for exenatide.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Exenatide · interactions on record

404 records

  • 3 severe
  • 359 moderate
  • 42 minor

Most severe, free to view

  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • MannitolA06AD16moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b83fcdeb-0628-44de-831a-eb8a24d2f954
GET /v1/drugs/b83fcdeb-0628-44de-831a-eb8a24d2f954?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "0.286",
  "form": "injektioneste, depotsuspensio, esitäytetty kynä",
  "route": "Ihon alle",
  "ddd_unit": "mg",
  "strength": "2 mg",
  "atc_label": "eksenatidi",
  "ma_number": null,
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": "EU/1/11/696/005-006",
  "fimea_rel_id": "REL51669",
  "authorised_at": "2018-08-27"
}

See everything about exenatide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.